PD-L1 Status in Refractory Lymphomas

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

(2016) Keith M. Kerr et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

(2016) I. Azzaoui et al.   BLOOD

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

(2016) K. Georgiou et al.   BLOOD

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference

(2016) V. M. Hubbard-Lucey et al.   Cancer Immunology Research

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy

(2015) T. Goldmann et al.   ANNALS OF ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1

(2015) Zoran Gatalica et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

(2015) R. W. Joseph et al.   Cancer Immunology Research

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

(2015) K. M. Mahoney et al.   Cancer Immunology Research

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

(2015) Colm Keane et al.   Lancet Haematology

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

(2014) David D. W. Twa et al.   BLOOD

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD